主题 - 自 2024 年 4 月 5 日起对杜伐单抗（新治疗适应症，肝细胞癌，一线单药治疗）进行效益评估的声明

{"title":"主题 - 自 2024 年 4 月 5 日起对杜伐单抗（新治疗适应症，肝细胞癌，一线单药治疗）进行效益评估的声明","authors":"","doi":"10.1055/a-2322-6582","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":503815,"journal":{"name":"Zeitschrift für Gastroenterologie","volume":"33 18","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Themen – Stellungnahme zur Nutzenbewertung von Durvalumab (neues Anwendungsgebiet, hepatozelluläres Karzinom, Erstlinie Monotherapie) vom 05. April 2024\",\"authors\":\"\",\"doi\":\"10.1055/a-2322-6582\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":503815,\"journal\":{\"name\":\"Zeitschrift für Gastroenterologie\",\"volume\":\"33 18\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Zeitschrift für Gastroenterologie\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1055/a-2322-6582\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zeitschrift für Gastroenterologie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/a-2322-6582","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}